SGP
Strong SellSinkerSpyGlass Pharma, Inc. · Healthcare · United States · $953M cap · $3.6M/day traded
$29.91 +5.0% · close 26 Oct · scored 27 Oct
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
As of 27 Oct 2026, MoatMap's StockRank for SpyGlass Pharma, Inc. (SGP) is 17/100, ranked against 24,000+ stocks in 35 markets (Quality 36, Value 26, Momentum 34, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT SPYGLASS PHARMA, INC.
Read
SpyGlass Pharma, Inc. is a clinical-stage ophthalmic pharmaceutical company focused on developing a proprietary sustained-release drug delivery platform for the treatment of glaucoma. Its innovative implantable technology aims to provide long-term, continuous medication delivery, addressing patient adherence challenges and potentially improving therapeutic outcomes. The company is poised to disrupt the glaucoma treatment market with its novel drug-device combination.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -1.17 | -1.62 | -1.25 | — | -2.51 | -2.50 | -2.81 | — |
| Shares | 31.9M | 31.9M | 31.9M | 0.0% | 33.4M | — | — | — |
| Debt | 0 | 3.9M | 1.6M | -59.4% | 1.6M | — | — | — |
| Equity | -33.0M | -60.5M | -98.8M | — | — | — | — | — |
| Op CF | -12.3M | -22.0M | -32.7M | — | -46.6M | — | — | — |
| Inv CF | -20.5M | 22.3M | -11.8M | — | — | — | — | — |
| Fin CF | 39.8M | 0.2M | 124.6M | — | — | — | — | — |
Not enough steady price history for a read yet.
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SGP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SGP | SpyGlass Pharma, Inc.(you) | $953M | 17 | Strong Sell |
| SPTX | Seaport Therapeutics, Inc. | $1.1B | 17 | Strong Sell |
| JBIO | Jade Biosciences, Inc. | $928M | 13 | Strong Sell |
| ARDX | Ardelyx, Inc. | $795M | 15 | Strong Sell |
| KURA | Kura Oncology, Inc. | $855M | 13 | Strong Sell |
| AVBP | ArriVent BioPharma, Inc. | $1.0B | 13 | Strong Sell |
| BCAX | Bicara Therapeutics Inc. | $1.1B | 14 | Strong Sell |
| AKTS | Aktis Oncology, Inc. | $875M | 12 | Strong Sell |
| NKTR | Nektar Therapeutics | $1.3B | 17 | Strong Sell |
| GLUE | Monte Rosa Therapeutics, Inc. | $925M | 11 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.2x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.